Project NIS-HANNA – A National, Prospective, Non-Interventional Study (NIS) of Nivolumab in Patients with Squamous Cell…

Basic data

Acronym:
NIS-HANNA
Title:
A National, Prospective, Non-Interventional Study (NIS) of Nivolumab in Patients with Squamous Cell Carcinom of the Head and Neck (SCCHN) progressing on or After Platinum-Based Therapy.
Duration:
01/10/2017 to 31/10/2022
Abstract / short description:
The European Commission approved nivolumab for the treatment of adult patients with SCCHN progressing on or after prior platinum-based on the positive opinion given by the committee for Medicinal Products for Human Use (CHMP). Approval was based on the results of CheckMate 141 trial.
Keywords:
Nivolumab
Hals-Nasen-Ohrenheilkunde
Head &Neck Cancer
Oncology
Otolaryngology

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Otolaryngology, Head and Neck Surgery; Polyclinic
Hospitals and clinical institutes
Faculty of Medicine
Help

will be deleted permanently. This cannot be undone.